Streetbeat News

Stock Prices

CVM

CEL-SCI has priced its public offering of 2.5 million shares at $2 per share, leading to a decrease in its stock price.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 10:16 am

KPTI

Karyopharm Therapeutics has received FDA Fast Track Designation for its drug Selinexor for Myelofibrosis, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 10:14 am

ARDS

Aridis Pharmaceuticals' shares are trading higher following positive feedback from the European Medicines Agency (EMA) on the company's proposed Phase 3 study AR-301 for pneumonia caused by Staphylococcus aureus in mechanically ventilated hospitalized patients.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 10:12 am

BPTS

Biophytis has signed a partnership with SEQENS to produce Sarconeos (BIO101), the company's main product. This has led to an increase in Biophytis' share prices.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 10:10 am

UBER

Uber Technologies' shares are expected to trade lower following a ruling by the California Supreme Court against the company. The lawsuit claimed that Uber should have covered UberEats drivers' work-related expenses.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 10:07 am

INFY

Infosys Limited has disclosed a $2 billion AI deal over 5 years with an existing client, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 10:03 am

AAPL

BAC

GS

NFLX

TSLA

The S&P 500 closed higher on Monday, despite increased market volatility following recent economic data from China. Major companies including Bank of America Corp, Tesla Inc, Goldman Sachs Group Inc, and Netflix Inc are set to release earnings this week. The Nasdaq 100 also gained, with shares of Apple Inc and Tesla Inc contributing to the rise. The CBOE Volatility Index rose 1.1% to close at 13.48 on Monday.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 9:45 am

MASI

Masimo Corp (MASI) shares are trading lower after the company reported Q2 2023 preliminary results and revised 2023 outlook. The company expects lower revenues than consensus due to delayed orders, lower sensor sales, a decline in customer conversion rate, and rising hospital labor expenses. The company plans to reduce costs in H2 2023 and expects non-healthcare revenues to be below expectations due to demand decline in the audio categories. The company also revised down its 2023 revenue guidance for both healthcare and non-healthcare businesses.

Portfolio Pulse from Lekha Gupta

July 18, 2023 | 9:41 am

ATVI

Baird analyst Colin Sebastian has downgraded Activision Blizzard (NASDAQ:ATVI) from Outperform to Neutral and set a price target of $90.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 9:31 am

ATVI

Atlantic Equities analyst Kunaal Malde has downgraded Activision Blizzard (NASDAQ:ATVI) from Overweight to Neutral and set a price target of $95.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 9:29 am